ZEVRA THERAPEUTICS INC
ZVRA
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Zevra Therapeutics is a commercial-stage rare disease pharmaceutical company whose drug development pipeline relies on animal testing as a standard regulatory requirement. The company’s research activities have been the subject of controversy and adverse publicity from animal rights groups, as documented by Cruelty Free Investors. In December 2025, Zevra was named as a defendant in a lawsuit, Commave Therapeutics SA v. Zevra Therapeutics, Inc., which involved an agreement to terminate a collaboration and license agreement (CLA) concerning compounds tested on animal subjects.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.